Clinical Trials Logo

Tenosynovial Giant Cell Tumor clinical trials

View clinical trials related to Tenosynovial Giant Cell Tumor.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05349643 Recruiting - Clinical trials for Tenosynovial Giant Cell Tumor

A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT

Start date: January 26, 2023
Phase: Phase 2
Study type: Interventional

AMB-051-07 is an Open-Label, Adaptive, Dose-Ranging Study with Long-Term Extension which will enroll approximately 48 adult subjects with TGCT for IA doses over a 24-week dosing period (Part 1) with a Part 2 OLE of 6 treatment and/or observational cycles of 12 weeks each followed by 12 weeks of follow-up.

NCT ID: NCT04703322 Recruiting - Clinical trials for Tenosynovial Giant Cell Tumor

A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan

Start date: March 15, 2021
Phase: Phase 2
Study type: Interventional

This phase 2, multicenter, two-part, open-label, single-arm study will be conducted in Japan and will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of pexidartinib in adult participants with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitation and not amenable to improvement with surgery.

NCT ID: NCT04635111 Recruiting - Clinical trials for Tenosynovial Giant Cell Tumor

A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment

Start date: January 7, 2021
Phase:
Study type: Observational [Patient Registry]

A study to evaluate the long-term risk of hepatic failure with TURALIO™ (pexidartinib) and the mechanism of liver injury based upon liver biopsy information among patients who received or are receiving TURALIO™ (pexidartinib) and experience hepatotoxicity.

NCT ID: NCT04192344 Recruiting - Neoplasms Clinical Trials

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor

Start date: January 20, 2020
Phase: Phase 1
Study type: Interventional

This is an open-label phase 1 study to determine the safety and tolebility of oral ABSK021 in patients with advanced solid tumor as well as the Recommended Phase 2 dose (RP2D) of oral ABSK021. Preliminary antitumor activity will also be assessed.